Navigation Links
Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer

BUFFALO, N.Y., May 22, 2013 /PRNewswire/ -- Empire Genomics announced today it has acquired an exclusive license for a patent pending novel genomic biomarker from Cornell University for use in developing a molecular diagnostic test that could help in diagnosing and determining treatment for patients with neuroendocrine (NEPC) prostate cancer. 

Neuroendocrine prostate cancer (NEPC) is a lethal variant of prostate adenocarcinoma (PCA) that can arise de novo, but more commonly arises after hormonal therapy for PCA. Little is known about the underlying molecular biology of NEPC or how and why some patients with PCA progress to a predominantly neuroendocrine phenotype. There is currently no effective therapy for NEPC, and most patients survive less than one year. The poor molecular characterization of NEPC accounts in part for the lack of disease specific therapeutics.

"Each year, approximately, 30,000 men will die of advanced prostate cancer, most of whom will be treated with androgen suppression therapy, however, it is impossible to know just how many of them developed NEPC because patients are not typically biopsied at that stage of their disease," said Dr. Brian Kelly , Director of Technology Commercialization and Liaison at the Weill Cornell Medical College office of the Cornell Center for Technology Enterprise and Commercialization (CCTEC). "We are delighted that Empire Genomics is now going to make this important diagnostic test available to this patient population and we look forward to working with the company and its seasoned management team."

"We are delighted to work with Empire Genomics to help develop a commercial grade assay to test for abnormalities one of the key driving genes of the most aggressive form of prostate cancer.  This clinical tool will be important as we move forward with precision medicine clinical trials for aggressive castration resistant prostate cancer lead by Dr. Himisha Beltran," said Mark Rubin , Homer T. Hirst Professor of Pathology in Oncology and the Director of the Institute for Precision Medicine.

Empire Genomics will launch a genetic test for NEPC that will diagnose NEPC Prostate Cancer later this year and seek to partner with pharmaceutical companies to use this assay for accelerating patient stratification in clinical trials. 

"We are very pleased to work with Drs. Rubin and Beltran and Cornell to commercialize this technology," said Anthony Johnson , CEO of Empire Genomics. "It is another exciting genomic tool that we have added to our exclusive precision medicine portfolio."

About Empire Genomics

Empire Genomics LLC is a firm in the field of molecular genomic testing specializing in oncology.  The company offers a wide range of best in class services that are used to detect genomic changes. The firm is a leader in the field of personalized medicine and helps clinicians, drug developers and researchers answer key questions in disease diagnosis, disease prognosis, and determining treatment for diseases. 


Sonya Stutts


This press release was issued through eReleases® Press Release Distribution. For more information, visit

SOURCE Empire Genomics, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
2. J. Craig Venter Institutes Mobile Genomics Lab Launches First School Visits in San Diego County
3. Real Time Genomics Secures a $5 Million Round of Funding to Expand Commercial Operations
4. Real Time Genomics and Knome Ink Deal to Integrate and Sell the RTG Variant Platform on knoSYS100 System
5. Real Time Genomics and J. Craig Venter Institute Embark on Strategic Research Initiative
6. Nimbix and Convey Partner for “The Accelerated Genomics Cloud” (TAGC) Promotion
7. Rosetta Genomics Reaches Settlement Agreement with Sanra Laboratories in Connection with Previous Sale of Parkway Clinical Laboratories
8. Real Time Genomics and Omicia Partner on a Platform for Integrated Genomic Analysis for Childhood Disease
9. Venter Institute-Led Team Recovers and Sequences Genome of Periodontal Pathogen from Biofilm in Hospital Sink using Single-Cell Genomics
10. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
11. Squished bug genomics: Insect goo aids biodiversity research
Post Your Comments:
(Date:10/7/2017)... ... October 06, 2017 , ... ... advanced instruments and applications consulting for microscopy and surface analysis, Nanoscience Instruments ... consulting, Nanoscience Analytical offers a broad range of contract analysis services for ...
(Date:10/7/2017)... WALTHAM, Mass. , Oct. 6, 2017 /PRNewswire/ ... pioneering work of three scientists, Jacques Dubochet, ... whose breakthrough developments in cryo-electron microscopy ... this technology within the structural biology community. The ... Scientific. Scientists can now routinely produce highly resolved, ...
(Date:10/6/2017)... ... October 06, 2017 , ... On ... and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The ... The event is free and open to the public, but registration is required. ...
(Date:10/5/2017)... ... October 05, 2017 , ... Understanding the microbiome, the millions ... human health. Gut Love: You Are My Future, the newest exhibit on display at ... it explores the human condition through the lens of the gut microbiome. , ...
Breaking Biology Technology:
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
Breaking Biology News(10 mins):